2-ethoxy-4-methyl-thiazole | 475645-27-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-ethoxy-4-methyl-thiazole
• 英文别名: 2-Aethoxy-4-methyl-thiazol；2-Ethoxy-4-methyl-1,3-thiazole
• CAS: 475645-27-3
• 化学式: C₆H₉NOS
• 分子量: 143.21
• InChiKey: ALXOJWFQHISSAW-UHFFFAOYSA-N

物化性质

• 沸点：
  71-72 °C(Press: 15 Torr)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-ethoxy-4-methyl-thiazole 在 三溴化磷 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以80%的产率得到4-甲基-1,3-噻唑-2(3H)-酮
  参考文献：
  名称：

  SYNTHESIS OF THIAAZAHETEROCYCLE NUCLEOSIDE ANALOGUES

  摘要：

  The syntheses of thiazinone, thiazinedione and thiazolinone base modified nucleoside analogues have been discussed in both the deoxy- and ribosyl series. Both inter- and intramolecular N-glycosylations were evaluated.

  DOI：

  10.1081/ncn-120006829
• 作为产物：
  描述：

  2-ethoxy-4-methyl-4-(N,N-dimethylamino)-2-thiazoline 在 碘甲烷 作用下， 以 二氯甲烷 为溶剂， 以100%的产率得到2-ethoxy-4-methyl-thiazole
  参考文献：
  名称：

  SYNTHESIS OF THIAAZAHETEROCYCLE NUCLEOSIDE ANALOGUES

  摘要：

  The syntheses of thiazinone, thiazinedione and thiazolinone base modified nucleoside analogues have been discussed in both the deoxy- and ribosyl series. Both inter- and intramolecular N-glycosylations were evaluated.

  DOI：

  10.1081/ncn-120006829

文献信息

• [EN] PYRIMIDINE, PYRIDINE AND TRIAZINE DERIVATIVES AS MAXI-K CHANNEL OPENERS.<br/>[FR] DÉRIVÉS DE PYRIMIDINE, PYRIDINE ET TRIAZINE EN TANT QU'OUVREURS DE CANAUX MAXI-K
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009125870A1

  公开（公告）日：2009-10-15

  A compound of formula (A); wherein ring A is an aromatic ring or a heteroaromatic ring; R1 is independently halogen, cyano, etc., each of X1, X2 and X3 is CR2 or nitrogen, R2 is independently hydrogen, etc., n is 0, 1, 2, 3 or 4; -D-Y is -O-CH2COOH, etc, and G is a substituted amino, a substituted heterocyclic group, etc, or a pharmaceutical acceptable salt thereof, has activities of opening BK channels.

  化合物的结构式（A）；其中环A是芳香环或杂芳环；R1独立地是卤素、氰基等；X1、X2和X3中的每一个是CR2或氮，R2独立地是氢等；n为0、1、2、3或4；-D-Y是-O-CH2COOH等；G是取代氨基、取代杂环基等，或其药用可接受盐，具有开放BK通道的活性。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：CASTRO Alfredo C.

  公开号：US20130053362A1

  公开（公告）日：2013-02-28

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.

  本文描述了调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及与激酶活性相关的疾病和病况的治疗方法，包括PI3激酶活性的化合物、药物组合物和治疗方法。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150175560A1

  公开（公告）日：2015-06-25

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein X, Y, Z, R 2 , R 3 , R 4 , p and q are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类钠通道抑制剂化合物及其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。具体实施例中，该化合物的结构由式I给出：其中X、Y、Z、R2、R3、R4、p和q如本文所述，以及制备和使用该化合物的方法以及含有该化合物的药物组合物。
• MACROCYCLIC SERINE PROTEASE INHIBITORS
  申请人：Parsy Christophe Claude

  公开号：US20100016578A1

  公开（公告）日：2010-01-21

  Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

  本文提供了一些大环丝氨酸蛋白酶抑制剂化合物，例如公式I所示，以及包含这些化合物的药物组合物和制备过程。还提供了这些化合物在治疗HCV感染的宿主中的使用方法。
• PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS
  申请人：Wang Tao

  公开号：US20120095017A1

  公开（公告）日：2012-04-19

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响特性的化合物，它们的制药组合物和使用方法。特别地，本发明涉及氮杂吲哚酮乙酰基哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂联合使用。更具体地，本发明涉及治疗HIV和艾滋病。